CCSD code A5420 – Therapeutic substance injection into CSF

Key takeaways

CCSD Code A5420 covers a therapeutic injection into the CSF as the sole procedure. The drug cost and any diagnostic lumbar puncture are billed elsewhere.

Intrathecal chemotherapy has its own code, A5480, so methotrexate or cytarabine doses never go under A5420.

Confirmation of CSF return before injection is a key documentation point for A5420 claims.

Epidural injections take A5200, A5210 or A5220 by spinal region, even when the therapeutic intent matches an intrathecal dose.

In Pabau’s claims management software, each claim pre-fills from the patient record and gets checked for missing authorization codes before submission.

What is CCSD Code A5420?

CCSD Code A5420 is the procedure code for injecting a therapeutic substance into the cerebrospinal fluid (CSF) as the sole procedure. Its official descriptor is “Injection of therapeutic substance into CSF – as sole procedure.” The CCSD added the “as sole procedure” qualifier in its November 2024 bulletin.

The code applies when a clinician gains intrathecal access, confirms CSF return, and delivers a drug directly into the subarachnoid space. A trial dose of intrathecal baclofen is the textbook case.

A5420 belongs to the CCSD (Clinical Coding and Schedule Development) schedule, maintained by the CCSD group. The major UK private medical insurers use it, such as Bupa, AXA Health, Aviva, Vitality, WPA and Healix. Bupa’s February 2026 schedule grades A5420 as Minor 2, with a £123 benefit.

The schedule is procedure-based, so each code describes one clinical act. Our CCSD codes hub lists the other procedures in the schedule. Four points define the scope of A5420:

• The route is intrathecal (into the subarachnoid space), not epidural or intravenous.
• A therapeutic substance is injected. A diagnostic tap with no injection uses A5530.
• The injection is the sole procedure, and chemotherapy has its own code, A5480.
• The code covers the procedural act only. The drug itself is billed separately.

What the procedure involves

An intrathecal injection reaches the subarachnoid space by passing a spinal needle through the dura mater. An epidural injection differs because the needle stops short of the dura. That distinction decides the code.

The standard procedural sequence is:

1. Patient positioning: typically lateral decubitus or seated, with the spine flexed to widen the interspinous space
2. Site preparation: sterile field established, with local anesthetic infiltrated into the skin and subcutaneous tissue
3. Needle placement: spinal needle advanced through the supraspinous and interspinous ligaments and the dura, into the subarachnoid space
4. CSF confirmation: the stylet is withdrawn, and clear CSF flowing freely from the needle hub confirms the intrathecal position
5. Substance injection: the therapeutic agent is introduced slowly, with drug identity, dose, concentration, and volume recorded
6. Post-procedure monitoring: the patient is observed for post-dural puncture headache, neurological change, or hemodynamic instability

Step 4 (CSF confirmation) is the clinical and documentation gateway. Without it, the procedure is not verifiably intrathecal and the A5420 claim is open to challenge.

Clinical indications: when A5420 is applicable

A5420 applies when an MHRA-licensed or clinically approved therapeutic agent is delivered into the intrathecal space as the sole procedure. The most common clinical scenarios are:

Two common intrathecal uses fall outside A5420. Intrathecal chemotherapy, such as methotrexate or cytarabine, is billed under A5480. Contrast medium for myelography is diagnostic rather than therapeutic, so it does not qualify.

The substance must be clinically indicated for the intrathecal route. An agent given intrathecally purely for convenience, when an effective intravenous alternative exists, may not meet an insurer’s medical necessity criteria.

What A5420 does not cover: exclusions and boundaries

Knowing the code’s exclusions prevents overbilling and reduces denials. Five boundaries apply:

• Epidural injections: the epidural and subarachnoid spaces are anatomically distinct. An injection that does not penetrate the dura is coded A5200 (cervical), A5210 (lumbar) or A5220 (thoracic), whatever the substance or intent.
• Diagnostic lumbar puncture: a tap performed only to obtain CSF for analysis is a different procedure. CSF sampling alone is coded A5530, which includes spinal manometry.
• Intrathecal chemotherapy: cytotoxic drugs delivered into the CSF are coded A5480, not A5420.
• Drug and supply costs: the procedural code covers the clinical act. Pharmaceutical costs are billed separately, through a drug item or the insurer’s own drug billing route.
• Imaging guidance: fluoroscopy or ultrasound guidance may be billed separately under an imaging code. Check the current CCSD rules, and whether the insurer allows it, before combining codes.

How A5420 differs from neighboring CCSD codes

The codes most often confused with A5420 share a needle at the spine but differ in anatomical target, purpose, or technique. Choosing the wrong one is a common source of A5420 denials. Three questions, asked in order, settle most cases.

Two of these codes have their own reference pages. A5530 covers a lumbar puncture with manometry, and its guidance sends an intrathecal injection to A5420 or A5480 instead. A5580 covers CSF infusion studies, a diagnostic test of CSF dynamics.

Confirm current descriptors against the CCSD technical guide before finalizing a code. Descriptors are reviewed periodically, and an older edition of the schedule may miss recent changes.

Documentation requirements for A5420 claims

A5420 claims are audited against the procedure note. Insurers check whether the record substantiates the intrathecal route. A note that is vague about needle depth or omits CSF confirmation counts as incomplete, and the claim can be denied on that basis alone.

Keeping structured patient records from consent through post-procedure monitoring reduces audit exposure and speeds up claim processing.

A complete procedure note for A5420 should include:

• Indication: the clinical diagnosis or condition justifying intrathecal delivery of the specific substance
• Needle placement: approach level (e.g. L3/L4), needle type and gauge, and confirmation that the dura was penetrated
• CSF confirmation: explicit documentation that clear CSF was seen flowing freely from the needle hub before injection, a key documentation point
• Substance detail: full drug name, formulation, dose, concentration, volume, and the route stated as intrathecal
• Monitoring: post-procedure observations, duration of monitoring, and any complications or adverse events
• Consent: evidence that the patient was told about the procedure, its risks, and the specific substance to be given

Digital forms with procedure-specific templates prompt for each mandatory field at the point of care. That way a missing field is caught at the bedside rather than at claims submission.

Billing A5420 with private medical insurers

CCSD Code A5420 is billed to the patient’s private medical insurer as part of the procedure invoice. Each insurer publishes its own fee schedule and benefit table based on the CCSD schedule. Benefit levels, shortfalls, and excess structures vary between insurers and between policy tiers.

For insurer-specific fee lookups, use the insurer’s own tool. The Healix fee schedule and the Vitality fee finder both support CCSD code searches. For Bupa, the Bupa code search tool gives current benefit values and billing rules.

For a fuller overview, see the Bupa CCSD code reference and the broader Bupa fee schedule guide.

Key billing considerations for A5420:

• Prior authorization: some insurers require pre-authorization for elective intrathecal procedures, particularly planned treatment courses. Requirements differ by insurer and policy type, so verify with the individual insurer before the procedure. An approval from one insurer never carries over to another.
• Hospital admission criteria: most intrathecal injections are performed in a day-case or inpatient setting. The insurer may require the admission itself to be authorized before the A5420 benefit is payable.
• Drug costs: pharmaceutical costs are not covered by A5420. They are submitted separately, typically through the hospital’s pharmacy billing or a drug item code. Confirm the insurer’s drug billing policy at the time of authorization.
• Shortfalls: where the specialist’s fee exceeds the insurer’s benefit, the patient pays the shortfall. Tell the patient about it before the procedure.

Common reasons A5420 claims are denied

Most A5420 denials fall into one of five categories, and each has a direct documentation or coding fix. Claims management software that tracks every claim’s status helps practices spot repeat denial reasons and fix the notes behind them.

How to appeal a denied A5420 claim

Most denied A5420 claims can be overturned if the appeal answers the stated denial reason with targeted documentation. Resubmitting the original note without correction rarely succeeds.

1. Identify the exact denial code: the insurer’s remittance or statement will include a reason code. The appeal must respond to that reason, not to a general dispute about the procedure.
2. Retrieve the procedure note: review it against the documentation checklist above. If CSF confirmation is missing or vague, ask the treating clinician for a dated addendum that clarifies what was observed at the time.
3. Obtain a clinical justification letter: for medical necessity denials, ask the treating anesthetist or pain specialist for a letter. It should explain why intrathecal delivery was needed over another route.
4. Check the authorization status: if the denial is for missing pre-authorization, check the insurer’s policy. Some offer an urgent exception pathway or retrospective authorization.
5. Submit within the insurer’s appeal window: appeal windows vary by insurer, so check the deadline in the denial notice. Late appeals are typically refused regardless of clinical merit.

How Pabau’s claims management software supports A5420 billing

Without a connected system, an A5420 claim gets assembled from scattered parts. The CSF confirmation sits in a free-text note, the authorization code in an email, and someone retypes both into the claim.

Pabau, the practice management platform we build, keeps those parts in one patient record. A digital form can make CSF confirmation a standard field in the procedure note. When you raise the claim, patient, treatment and insurer details pre-fill from that record.

Validation checks flag missing details, such as membership numbers and authorization codes, before the claim goes out. UK practices can submit through Healthcode or by email, then follow each claim through to payment in one view.

Get A5420 claims right the first time

Pabau pre-fills CCSD claims from the patient record and flags missing authorization codes before submission. Track every claim from submitted to paid in one view.

Book a demo

Conclusion

Code A5420 only when a therapeutic drug goes into the CSF as the whole procedure. Chemotherapy belongs to A5480, a diagnostic tap to A5530, and an epidural to its regional code.

Once the code is right, the procedure note decides whether the claim pays. Make CSF confirmation a required line in your intrathecal template, and one of the most preventable denials never reaches the insurer.

Book a demo to see how Pabau turns a complete procedure note into a pre-filled A5420 claim.

Continue your research

Managing CCSD codes across Bupa claims? Bupa CCSD codes reference covers the full Bupa schedule and how CCSD codes map to its fee structure.

Coding the diagnostic tap instead? CCSD Code A5530 explains lumbar puncture billing, including when an injection moves the claim to A5420.

Measuring CSF dynamics rather than injecting? CCSD Code A5580 covers CSF infusion studies and the pressure recording insurers expect.

Need a broader view of insurer fee schedules? Bupa procedure codes fee schedule explains how UK private medical insurers structure CCSD-based benefits.

Seeing the same denial reasons repeat? Denial management in healthcare sets out a process for tracking and preventing repeat denials.

Frequently asked questions